Flint, MINCT07118202Now EnrollingIRB Ready

Hepatocellular Carcinoma Recurrent Clinical Trial in Flint, MI

Access cutting-edge hepatocellular carcinoma recurrent treatment through this clinical trial at a research site in Flint. Study-provided care at no cost to qualified participants.

Sponsored by Barbara Ann Karmanos Cancer Institute

Quick Self-Assessment

See if you qualify for this Flint location

Preparing your pre-screening questions…

Expert Care in Flint

Access hepatocellular carcinoma recurrent specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hepatocellular carcinoma recurrent treatment provided free

Apply for This Flint Location

Check if you qualify for this hepatocellular carcinoma recurrent clinical trial in Flint, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Flint

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Flint site if eligible
  4. 4Begin participation

About This Hepatocellular Carcinoma Recurrent Study in Flint

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device

Sponsor: Barbara Ann Karmanos Cancer Institute

Who Can Participate

Inclusion Criteria

Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)
Patients who have failed at least two lines of therapy\
or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy.
Patients with evaluable disease
Patients must be ≥ 22 years old and must be able to understand and sign an informed consent.
Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.
Patients with a life expectancy of at least 3 months

Exclusion Criteria

Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
Patients taking any other investigational drugs
Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device
Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study.
Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.
Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)
Patients with a known severe (e.g., anaphylactic) allergy to nickel

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Flint?

Yes, this clinical trial (NCT07118202) has an active research site in Flint, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatocellular Carcinoma Recurrent Treatment Options in Flint, MI

If you're searching for hepatocellular carcinoma recurrent treatment options in Flint, MI, this clinical trial (NCT07118202) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Flint research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatocellular carcinoma recurrent specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatocellular carcinoma recurrent clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Flint, MI

See all liver cancer clinical trials recruiting in Flint — not just this study.

Browse Liver Cancer Trials in Flint →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Flint?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Flint, MI